Brevan Howard Trims AbbVie Stake by 59%

Hedge fund sells over 26,000 shares of pharmaceutical giant in Q3

Mar. 16, 2026 at 8:53am

Got story updates? Submit your updates here. ›

Brevan Howard Capital Management LP reduced its holdings in AbbVie Inc. (NYSE: ABBV) by 59% during the third quarter, according to a recent SEC filing. The institutional investor sold 26,408 shares, leaving it with 18,338 shares of the pharmaceutical company's stock valued at $4.2 million as of the end of the quarter.

Why it matters

AbbVie is one of the world's largest pharmaceutical companies, known for blockbuster drugs like Humira. Tracking changes in ownership by major institutional investors like Brevan Howard can provide insights into market sentiment around the stock.

The details

Brevan Howard, a prominent global macro hedge fund, sold a significant portion of its AbbVie position in Q3 2026. The firm now holds just 18,338 shares of the company, down from 44,746 shares at the end of the prior quarter.

  • Brevan Howard made the share sales during the third quarter of 2026.

The players

Brevan Howard Capital Management LP

A global macro hedge fund that has reduced its stake in pharmaceutical giant AbbVie.

AbbVie Inc.

A large biopharmaceutical company known for drugs like the blockbuster Humira.

Got photos? Submit your photos here. ›

The takeaway

Brevan Howard's decision to trim its AbbVie position by over half could signal broader market concerns about the pharmaceutical company's growth prospects or valuation. However, AbbVie remains a major holding for many institutional investors, underscoring its status as a blue-chip healthcare stock.